Medical/Pharmaceuticals

Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist

SHANGHAI, June 16, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces positive topline results of safety and pharmacodynamic ...

2021-06-16 21:00 4144

Spark Aligners Does It Again With Market Leading Innovation And New FDA Approval To Give Doctors Greater Control And Flexibility

-- New Features in Release 11 Combined with Expanded Indication for Mixed Dentition  to Treat Kids and Teens is a Home Run for Doctors -- BREA, Calif., June 16, 2021 /PRNewswire/ -- Ormco Corporation, a global leader of orthodontic solutions, today announced it has received FDA clearance to tre...

2021-06-16 20:45 2301

Clarivate Report Demonstrates that Nations or Institutions with Diverse Research Priorities Respond More Comprehensively to Unprecedented Scientific Challenges

Forward-looking approach offers a valuable new tool for anticipating and preparing for the unexpected LONDON, June 16, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today released a new Global ...

2021-06-16 15:00 9584

Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute to co-develop novel biotherapies in cancer t...

2021-06-16 13:08 9151

Carepool Asia - Malaysia's first multi-disciplinary digital healthcare platform that offers unlimited telehealth appointments

KUALA LUMPUR, Malaysia, June 16, 2021 /PRNewswire/ -- CAREPOOL ASIA, an innovative digital health platform launches its new, affordable digital health packages, the first telehealth platform that offers unlimited consultation services via a monthly subscription fee, as low asRM170 per month for t...

2021-06-16 12:35 3263

Medidata Becomes First Company to Offer End-to-End, Unified, Secure Platform for Decentralization of Clinical Trials (DCT)

* The first company in the world to unify direct patient data capture technology with study oversight and monitoring, Medidata redefines end-to-end decentralization for sponsors and CROs * The unique Medidata Trial Dial™ concept provides the industry's highest level of customization for c...

2021-06-16 09:11 3547

 Smith+Nephew launches Real Intelligence and CORI™ Surgical System, next generation robotics platform, in Australia and New Zealand

LONDON, June 16, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its Real Intelligence suite of enabling technology solutions including its next generation robotics platform, the CORI Surgical System, inAustralia and New ...

2021-06-16 06:00 13147

Galimedix Accelerating Development of Its Next-Generation Oral Anti-Amyloid Beta Drug GAL-201 for Alzheimer's Disease

Following recent FDA approval of Biogen's Alzheimer antibody drug ADUHELM (TM), targeting oligomers of amyloid beta, Galimedix aims for first patients with its GAL-201 oral small molecule drug within one year. KENSINGTON, Md., June 16, 2021 /PRNewswire/ -- Galimedix, Inc., a clinical-stage bioph...

2021-06-16 04:38 1345

VNTC confirms Dong-A ST its sole distributor of scoliosis brace Spinamic in South Korea

SEOUL, South Korea, June 15, 2021 /PRNewswire/ -- VNTC, a MedTech company, announced onJune 15 its signing of a Korean distributorship contract with Dong-A ST. The two companies are now able to provide a wide range of services both at home and abroad through mutual cooperation in sales and market...

2021-06-16 00:00 3813

Frontera Therapeutics Starts GMP Manufacturing Facility Construction

SUZHOU, China, June 15, 2021 /PRNewswire/ -- On June 9, 2021, Frontera Therapeutics Co., Ltd. ('Frontera') held a groundbreaking ceremony to start the construction of its Suzhou facility in bioBAY of Suzhou Industrial Park (SIP), Jiangsu, China. President of Suzhou Frontera, Dr. Xinyan Li, hosted ...

2021-06-15 23:32 2281

BIO Digital Taiwan Day will be held on June 22

TAIPEI, June 15, 2021 /PRNewswire/ -- With COVID-19 dramatically changing the healthcare industry, organizations have been forced to adapt their practices and embrace digital transformation - and now, as vaccines become more available in the developed countries, it is time to look into the future...

2021-06-15 23:00 2928

Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma

SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with theJoan & Sanford I Weill Medical College of Cornell University in the United States, to launch ...

2021-06-15 22:00 11785

Qynapse to present clinical results of QyScore® for Alzheimer's Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology

BOSTON, June 15, 2021 /PRNewswire/ -- QYNAPSE Inc., a medical technology company commercializing the most advanced artificial intelligence neuroimaging platform, today announced it will present clinical data on QyScore® for Alzheimer's disease and multiple sclerosis at the 7th Congress of the Eur...

2021-06-15 18:00 3144

Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China

SAN FRANCISCO and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2021-06-15 12:00 5369

iAPPS Health Group, a Fin-MedTech company, announces former Senior Minister of State for Health Dr. Lam Pin Min as its Chairman

SINGAPORE, June 15, 2021 /PRNewswire/ -- iAPPS Health Group ("iHG") announced the appointment of former Senior Minister of State for Health, Dr. Lam Pin Min, as Chairman of its board of directors. Dr. Lam Pin Min brings with him a wealth of relevant experience as a veteran in the healthcare...

2021-06-15 09:35 3533

The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, June 15, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients wit...

2021-06-15 09:06 2471

The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, June 14, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients wit...

2021-06-15 08:46 1702

Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors

SUZHOU, China, and ROCKVILLE, Md., June 15, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Investigational Ne...

2021-06-15 07:39 18285

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial

* 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest * 91% efficacy in high-risk populations * 100% efficacy against variants "not considered Variants of Concern/Interest" * All COVID-19 hospitalizations/death occurred in the placebo group * Company...

2021-06-15 07:06 6444

BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development

VANCOUVER, British Columbia, June 15, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys"), is pleased to announce today that the US Food and Drug Administration (FDA) has reviewed its Pre-IND request for a Type B review of its CoviDTH program and has d...

2021-06-15 04:19 16231
1 ... 646647648649650